tbuckley/cabot-search huggingface dataset:
Determining frequency and reasons associated to refusal of colorectal cancer screening at a reference center in Mexico.
Authors: Mónica Isabel Meneses Medina, Luis Guillermo Anaya Sanchez, Jorge Humberto Hernandez-Felix, Lucero Itzel Torres Valdiviezo, Vanessa Rosas Camargo, Alberto Cedro-Tanda, Luis Federico Uscanga Dominguez, Martin Lajous, Francisco Valdovinos Aldaca, Fagundo Sierra Reynerio, Alejandro Noguez-Ramos, Fidel David Huitzil Melendez
Journal: Journal of Clinical Oncology (2022)

67 Background: in Mexico, Colorectal Cancer (CRC) is a leading cause of cancer death, yet population-based screening programs are lacking. In our center, a cohort was created to validate a risk calculator to detect advanced colorectal neoplasia, and to understand barriers to implement a CRC screening program. We aimed to determine frequency and reasons associated to rejection of CRC screening in our population. Methods: from August 2019 to March 2020 (early close owing to COVID-19 pandemic) asymptomatic individuals between 50 and 75 years-old with standard-risk for CRC, without previous screening for CRC, from the outpatient internal medicine clinic at a tertiary care center in Mexico City, received standardized information on the importance of CRC screening and were invited to perform both Fecal Immunochemical Test and a screening colonoscopy within a clinical study at no cost. Individuals who rejected participation were given a 10-item questionnaire to select reasons for refusal, as many items as applied. Here we present two groups: 1) individuals who refused to receive information and to perform screening studies, and 2) individuals who refused to participate after receiving information. Results: 162 patients were invited to participate, 77 (47%) refused: 48 rejected immediately (group 1) and provided 51 reasons, and 29 declined after having received standardized information about CRC screening (group 2) and provided 30 reasons. Demographics for 77 patients were: 54 (70.1%) women, median age 66 (IQR 58-71) years. Main reasons for rejection in both groups were: “I do not have time” in 24 (29.6%) times, “I am not interested” in 23 (28.4%) times, and “I am scared” in 14 (17.3%) times (Table). Conclusions: in our cohort, we identified that nearly half of the population invited to participate in a CRC screening program refused. Main reasons were lack of time, lack of interest and fear. This may translate poor understanding on the importance of measures to prevent CRC, and absence of education programs to recall its importance. In order to increment participation in CRC screening, education and awareness campaigns should be implemented.[Table: see text]
Chronic $beta;-adrenergic stimulation induces dose-dependent myocardial proinflammatory cytokine expression and hypertrophy independent of end-systolic wall stress David R. Murray, Sumanth D. Pradhu, Bysani Chandrasekar. University of Texas Health Science Center, San Antonio, TX, University of Louisville, Louiseville, KY
Journal: Journal of the American College of Cardiology (2001)
A phase 1 study of ABX196 in combination with nivolumab in patients with previously treated hepatocellular carcinoma (HCC).
Authors: Darren Sigal, Munveer Singh Bhangoo, Catherine T. Frenette, Sunyoung S. Lee, Christine Fark, Paul Gineste, Anais Vissian, Luc Teyton, Tillman E. Pearce, Ahmed Omar Kaseb
Journal: Journal of Clinical Oncology (2022)

429 Background: ABX196, a synthetically modified α-galactosylceramide (α-GalCer), activates invariant NKT (iNKT) cells and produced anti-tumor activity in Hepa 106 xenograft HCC models. Pre-administration of anti-PD1 antibodies prevented α-GalCer-induced iNKT cell anergy and may also enhance iNKT cell-induced T cell response. We report on a phase 1 study evaluating the combination of ABX196 plus nivolumab (N) in HCC patients previously treated with at least 1 line of prior systemic therapy. Methods: In a 3+3 dose escalation design, intramuscular ABX196 was dosed at 0.1, 0.2, or 0.4 µg 120 mins after N infusion on day 1 of every other 28-day cycle. N (240mg) was administered intravenously on day 1 and 15 of each cycle. Key objectives were to assess safety, MTD, and signs of clinical benefit. Study endpoints included incidence and severity of AEs, laboratory parameters, DLTs, ORR, and PFS. Results: 10 patients (8 males, 2 females) were enrolled: median age, 66y (49-76y); median # of prior systemic therapies, 2 (1-3), including 9 patients with prior immune checkpoint inhibitor (ICI) therapy; median # of ABX196 doses, 2.5 (1-8). There were 76 AEs (95% G1/G2) and 1 non-treatment related SAE. Common non-serious AEs included diarrhea (6), malaise/fatigue (6), AST/ALT increase (6), and only 1 injection site reaction. Maximum administered dose was 0.4 μg; MTD not reached. Clinical benefit was observed in 5 patients (50%) including 1 patient with a PR (ORR 10%) and 4 patients with SD (40%). Of these 5 patients, 3 had viral hepatitis. Median PFS for all patients was 113.5 days (49-450 days), but for those with clinical benefit it was 276 days (172-450 days). Conclusions: ABX196 plus N was very well tolerated without any DLTs or treatment emergent SAEs. In this small but heavily pre-treated HCC population, ABX196 plus N demonstrated promising signals of clinical benefit, including in patients with previous ICI therapy. These results support further clinical development of ABX196 in the front-line HCC setting. Clinical trial information: NCT03897543. [Table: see text]
JAMA 100 Years Ago
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What is a geriatrician?
Authors: V. A. Portnoi
Journal: JAMA (1980)

THE COMMITTEE on Aging and Medical Education of the Institute of Medicine (IOM) at the National Academy of Sciences has released a report that may have an important impact on the future of medical education and residency training programs. One of the most important recommendations of the committee was to incorporate "a broad and relevant body of knowledge" on aging into the formal curricula of medical students and to require every physician (except pediatricians) to have an appropriate exposure to the principles of geriatric medicine.<sup>1</sup> While realizing that there are features specific to geriatric practice, the committee failed to provide a definition of such a practice and recommends against the establishment of a subspecialty of geriatrics. Paul Beeson, chairman of the IOM committee, said that geriatric medicine should be considered as an academic specialty, rather than a practical field, comparable with infectious diseases, which "is weakly represented as a
The differential influence of current HRT and age on vascular function in women: The NHLBI-Sponsored WISE study B. Delia Johnson, C. Noel Bairey Merz, Steven E. Reis, Richard Holubkov, Vera Bittner, Carl J. Pepine, William J. Rogers, Nathaniel Reichek, Barry L. Sharaf, Richard A. Kerensky, Sheryl F. Kelsey, George Sopko. University of Pittsburgh, Pittsburgh, PA
Journal: Journal of the American College of Cardiology (2001)
AUTOIMMUNIZATION AND THE DOG
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Overview of the Eye in Diabetes
Authors: Anil Negi, Stephen A Vernon
Journal: Journal of the Royal Society of Medicine (2003)

The three papers in this symposium are based on presentations to an RSM meeting on the Diabetic Eye, held on 9 April 2003. The matter is particularly topical because the National Service Framework for Diabetes calls for a high-quality retinal screening programme. After a review of the various ophthalmic conditions likely to be encountered in diabetic patients (A Negi, S A Vernon) we proceed to the most important, diabetic retinopathy, with a discussion of screening methods (D M Squirrell, J F Talbot) and an account of laser treatments (J G F Dowler). Colour versions of the clinical photographs are available online [www.jrsm.org]. Publication was coordinated by Professor Susan Lightman, of Moorfields Eye Hospital, London, UK.
Abstract 17082: ECG Screening in North Texas High School Students: A Randomized, Pilot Feasibility Study
Authors: Karl Gordon Patti, Matthew Cain, James Daniels, Sander van Lanen, Gary Parizher, William Scott, Mark S Link, John P Higgins, Jonathan A Drezner, Kimberly G Harmon, Rachel Lampert, Benjamin D Levine
Journal: Circulation (2018)

Introduction: The death of young athletes is devastating to families and communities. Despite routine pre-participation screening, 80–100/yr die or suffer cardiac arrest, with 65% occurring in high school athletes. AHA/ACC recommendations for pre-participation screening do not include routine electrocardiogram (ECG), in contrast to some international guidelines. Methods: We designed a pilot study to test feasibility of a larger trial, scaled to 1% of the estimated 800,000 participants required to power for detection of sudden death/arrest. Athletes and band members enrolled in eight high schools in two Texas school districts were randomized in block fashion to standard screening alone versus the addition of ECG. ECGs were interpreted using CardeaScreen software, over-read by an independent expert. Students with abnormal ECGs received cardiology evaluation at no cost. Text messages assessing for cardiac events or hospitalizations were sent to both groups biannually. Results: Of the ~8,000 eligible students, the intervention group enrolled 847 students who received ECG (21%); the non-intervention group enrolled 655 students (16%). CardeaScreen identified 20 of 847 ECGs as abnormal (2.4%) and the expert identified 19 as abnormal (2.2%) Six of 20 ECGs (30%) identified as abnormal by CardeaScreen were over-read as normal, and 5 of 827 ECGs (0.6%) identified as normal by CardeaScreen were over-read as abnormal (PPV 70%, NPV 99.4%). Twenty-five follow up visits were attempted, 22 were completed (88%), and specialist referrals were sent for 6 (29%). New diagnoses included Wolf-Parkinson-White syndrome, coronary anomaly, and depressed LV function. Follow up with SMS surveys yielded 737 responses at 6 months and 441 responses at 16 months. No sudden cardiac death or arrest was reported. Conclusion: Randomized ECG testing and follow-up of high school students is feasible, though with low enrollment and relatively low yield. Automated ECG interpretation is viable but leads to significant false + results. Low participation in enrollment and follow up present challenges to a large-scale ECG screening study powered for clinical events. Possible solutions include an “opt-out” enrollment strategy and use of alternate follow up methods such as social media.
ENDOV upregulation and outcomes in females with colorectal adenocarcinoma.
Authors: Chandur Bhan, Chenyu Sun, Nimarta Bheesham, Fnu Shakuntulla, Zain I. Siddiqui, John Pocholo W. Tuason, Arpana Paudel, Marwan K. Ahmed, Na Hyun Kim, Burhan Memon, Humaed Mohammed Abdul, Yasmin A. Gerais, Apurwa Prasad, Qurrat-ul-ain Abid
Journal: Journal of Clinical Oncology (2022)

175 Background: Colorectal adenocarcinoma (COAD) is a common cancer in gastrointestinal tract. Endonuclease V (ENDOV), an enzyme with specificity for deaminated adenosine (inosine) in nucleic acids, was found to be involved in the development of certain cancers. Thus, this study was performed to explore the effects of ENDOV on the prognosis of COAD. Methods: RNA-sequencing FPKM data and corresponding clinical information of 41 normal tissues and 480 tumor tissues of COAD were acquired from The Cancer Genome Atlas (TCGA). Then ENDOV expression differences between the normal and cancer tissues were compared with Wilcoxon rank-sum test via ‘limma’ package. Overall survival (OS) and disease specific survival (DSS) analyses were conducted by Kaplan–Meier (K–M) method via ‘survminer’ package. Subgroup analyses of different genders were also performed. Results: The expression of ENDOV was downregulated in tumors compared with normal tissues (p &lt; 0.001). However, higher expression of ENDOV is associated with worse OS (HR: 1.83, 95%CI: 1.23-2.73, P = 0.003) and DSS (HR: 1.75, 95%CI 1.06-2.91, P = 0.03). Subgroup analysis found that higher expression of ENDOV was associated with worse OS (HR: 2.17, 95%CI 1.18-3.98, P = 0.012) in females, but not in males (HR: 1.48, 95%CI 0.86-2.53, P = 0.158). As for DSS, higher expression of ENDOV was also correlated with worse outcome (HR: 2.36, 95%CI 1.07-5.19, P = 0.033) in females, but not in males (HR: 1.45, 95%CI 0.73-2.86, P = 0.287). Conclusions: ENDOV is overall downregulated in COAD tumor samples. However, higher expression of ENDOV in certain COAD patients is associated worse OS and DSS in females but not in males. This indicates the potential role of ENDOV in predicating the prognosis of COAD in female patients.
Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women
Authors: Neil Carleton, Azadeh Nasrazadani, Kristine Gade, Sushil Beriwal, Parul N Barry, Adam M Brufsky, Rohit Bhargava, Wendie A Berg, Margarita L Zuley, G J van Londen, Oscar C Marroquin, Darcy L Thull, Phuong L Mai, Emilia J Diego, Michael T Lotze, Steffi Oesterreich, Priscilla F McAuliffe, Adrian V Lee
Journal: The Lancet Healthy Longevity (2022)

Age is one of the most important risk factors for the development of breast cancer. Nearly a third of all breast cancer cases occur in older women (aged ≥70 years), with most cases being oestrogen receptor-positive (ER+). Such tumours are often indolent and unlikely to be the ultimate cause of death for older women, particularly when considering other comorbidities. This Review focuses on unique clinical considerations for screening, detection, and treatment regimens for older women who develop ER+ breast cancers—specifically, we focus on recent trends for de-implementation of screening, staging, surgery, and adjuvant therapies along the continuum of care. Additionally, we also review emerging basic and translational research that will further uncover the unique underlying biology of these tumours, which develop in the context of systemic age-related inflammation and changing hormone profiles. With prevailing trends of clinical de-implementation, new insights into mechanistic biology might provide an opportunity for precision medicine approaches to treat patients with well tolerated, low-toxicity agents to extend patients' lives with a higher quality of life, prevent tumour recurrences, and reduce cancer-related burdens.
New York Rheumatism Association
Authors: William Kammerer, Jack Dordick, Bernard Rogoff, Morris Ziff, Rubin Klein, Charles Plotz, Vincent Contreras, Frank Schmid, A Gutman, T Yu
Journal: Annals of the Rheumatic Diseases (1955)

A preliminary report on the use of the hypospray jet injector for intra-articular injection is presented.The injector forces a fine jet of the material through the skin and subcutaneous tissues, and now, we believe, through the articular capsule.Various joints of an unembalmed cadaver were initially injected by the hypospray, using trypan blue.On dissection, the dye was found to be deposited in the joint cavity and to some extent in the periarticular tissues.When diodrast was injected into the joints of patients the periarticular localization of the material was evident.In other studies with the hypospray, 34 5 and 59-6 per cent. of trypan blue in one instance, and 1 -2 and 13-6 per cent. of hydrocortisone in another instance, could be recovered from the knee and elbow, respectively.Clinical studies were limited to small joints of the hands and wrists of 25 patients with rheumatoid arthritis.One hundred injections were made, 15 mg.hydrocortisone acetate in 0 * 6 ml.using the smaller joints, and 25 mg. in I ml.for the wrist and larger joints.After initial trials with the conventional instrument, a special instrument 18 per cent.more powerful was used; this latter gave major improvement in fifteen of eighteen proximal interphalangeal joints, in five of six metacarpophalangeal joints, and in six of eleven wrist joints.No serious complications have resulted.Mild pain of seconds to minutes is occasionally reported by some patients, especially with small joints.The hypospray is almost uniformly preferred to needle injection.
Double threat of COVID-19 and influenza
Authors: Talha Khan Burki
Journal: The Lancet Respiratory Medicine (2020)

At the time of publication, it looks like the second wave of COVID-19 is well underway in Europe. The weekly tally of new cases has been steadily rising for more than 2 months, but the past few weeks have seen accelerated transmission. Cases have also been trending upwards in the USA. Oct 14, 2020, saw the nation register the highest number of new cases of COVID-19 since Aug 7. In general, countries are much better prepared than they were when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first exploded onto the scene.
Journal of Experimental Medicine, New York
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Psychology of Pandemics
Authors: Steven Taylor
Journal: Annual Review of Clinical Psychology (2021)

This article reviews the current state of knowledge and promising new directions concerning the psychology of pandemics. Pandemics are disease outbreaks that spread globally. Historically, psychological factors have been neglected by researchers and health authorities despite evidence that pandemics are, to a large extent, psychological phenomena whereby beliefs and behaviors influence the spreading versus containment of infection. Psychological factors are important in determining ( a) adherence to pandemic mitigation methods (e.g., adherence to social distancing), ( b) pandemic-related social disruption (e.g., panic buying, racism, antilockdown protests), and ( c) pandemic-related distress and related problems (e.g., anxiety, depression, posttraumatic stress disorder, prolonged grief disorder). The psychology of pandemics has emerged as an important field of research and practice during the coronavirus 2019 (COVID-19) pandemic. As a scholarly discipline, the psychology of pandemics is fragmented and diverse, encompassing various psychological subspecialties and allied disciplines, but is vital for shaping clinical practice and public health guidelines for COVID-19 and future pandemics.
Endoscopy International Open – recently published
Journal: Endoscopy (2021)

Comment on: Benefit, tolerance, and safety of hybrid argon plasma coagulation for treatment of Barrett's esophagus: US pilot studyEndosc Int Open 2021; 09(12): E1870-E1876DOI: 10.1055/a-1492-2450 Comment on: Effect of adding magnifying BLI, magnifying NBI, and iodine staining to white light imaging in diagnosis of early esophageal cancerEndosc Int Open 2021; 09(12): E1877-E1885DOI: 10.1055/a-1583-9196 Comment on: Micro-computed tomography: A novel diagnostic technique for the evaluation of gastrointestinal specimens Endosc Int Open 2021; 09(12): E1886-E1889DOI: 10.1055/a-1546-8063
London.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal